Opendata, web and dolomites

SEPSCAV SIGNED

SCAVENGING ON SEPSIS. DEVELOPMENT OF SEPSIS SPECIFIC DRUGS FROM HUMAN SCAVENGER RECEPTORS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SEPSCAV" data sheet

The following table provides information about the project.

Coordinator
SEPSIA THERAPEUTICS SL 

Organization address
address: PLAZA EUROPA NUM 9 11 PLANTA 13 TORRE INBISA
city: L HOSPITALET DE LLOBREGAT
postcode: 8908
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.sepsia.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SEPSIA THERAPEUTICS SL ES (L HOSPITALET DE LLOBREGAT) coordinator 50˙000.00

Map

 Project objective

Sepsis is a major a life-threatening condition caused by bacterial or fungal infections leading to cardiovascular collapse (septic shock), multi-organ dysfunction syndrome (MODS) and death, and claims more lives that bowel and breast cancer combined. The human Scavenger-receptors are naturally occurring proteins on some blood cells that interact and neutralize core structural components of microbes, providing a novel therapeutic strategy for wide-spectrum sepsis treatment and an alternative to current antibiotic and adjunctive therapeutic approaches of limited success. Sepsia Therapeutics is a R&D start up company developing SIXTIDE, a peptide-drug based on human scavenger lymphocyte receptor CD6, with dual bactericidal and anti-inflammatory action, which protects mice from death in experimental sepsis, in a time- and dose-dependent manner. SIXTIDE mode of action inhibits bacterial growth and blocks the pro-inflammatory properties of bacterial toxins. Sepsia Therapeutics holds IPR on the use of CD6 and CD6 derivatives in the treatment of infection and inflammation disorders and aims for market entry through injectable SIXTIDE.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEPSCAV" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEPSCAV" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.

Read More  

TalentVision (2019)

INSIGHTS FOR TALENT ASSESSMENT USING COMPUTER VISION TECHNIQUES FROM NEURO PSYCHOLOGY

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More